905 / 1851
The primary end points were:
a) 2-year progression-free survival (PFS)
b) acute treatment-related toxicity.
No evidence of neurocognitive decline
within the 12-month post-
rdWBRT
follow-up
period. One case of grade 4 neutropenia
57% in the entire population
79% in the patients who received rdWBRT
Shah et al. JCO 2007;25
Feasibility of ”reduced dose” WBRT